Sichuan Biokin Stock Hits Day Low of CNY 279.31 Amid Price Pressure

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 4.44% to reach an intraday low of CNY 279.31. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Sichuan Biokin has faced a 6.39% decrease, and its monthly performance reflects a significant drop of 17.26%. Year-to-date, the stock has declined by 12.5%, while its annual performance shows a decrease of 13.0%. Despite a remarkable three-year performance of 229.04%, the recent trends indicate a challenging period for the company. Financial metrics reveal that the company has reported negative results for the last four consecutive quarters, with net sales for the first nine months at CNY 2,065.9 million, reflecting a decline of 63.52%. Additionally, the net profit for the same period stands at CNY -500.37 million, marking a decrease of 112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million, further highlighting the company's current financial difficulties.